Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page now displays the ClinicalTrials.gov record for NCT03955471, with study details such as eligibility criteria, locations, outcome measures, results, and study documents.
    Difference
    73%
    Check dated 2026-11-08T14:35:41.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The study record page displays a 403 Forbidden message with a Home button in place of its study content. The site revision label changed from v3.7.2 to v3.8.0.
    Difference
    0.6%
    Check dated 2026-11-01T15:49:14.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website updates and says the agency is transitioning from using “Artificial Intelligence” to “Super Intelligence” terminology.
    Difference
    1%
    Check dated 2026-10-25T15:38:20.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.1 to v3.7.2; the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T20:32:36.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T20:35:08.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    A 403 Forbidden page is now displayed for the study record NCT03955471, replacing the previously visible study details and navigation. This indicates the page is blocked or failing to load, preventing access to the study information.
    Difference
    20%
    Check dated 2026-09-20T20:06:56.000Z thumbnail image

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.